|
||
| |||||||
|
|
BioInvent’s preferential rights issue is oversubscribed 9th December 2005 Lund, Sweden: The subscription period for BioInvent International AB’s (SAX:BINV) preferential rights issue ended on Friday 2 December and interest in participation in the issue was substantial. The issue was fully guaranteed and was oversubscribed. 26 per cent of the shares were subscribed for without preferential rights and these shares have been allocated to BioInvent’s Board of Directors in accordance with the issue decision. The issue has raised SEK 160 million for BioInvent before issue costs. The number of shares in the company following the issue is 47,160,889, which represents a share capital of 23,580,444.50. Trading in the new shares is expected to start around 22 December 2005. ”We have four product candidates in development phase and this issue of shares enables BioInvent to push these forward in the value chain in order to generate value for our shareholders,” says Svein Mathisen, CEO of BioInvent. -- THE END -- For more information BioInvent International AB Svein Mathisen Cristina Glad President and CEO Executive Vice President Phone: +46 (0)46 286 85 67 Phone: +46 (0)46 286 85 51 Mobile: +46 (0)708 97 82 13 Mobile: +46 (0)708 16 85 70 E-mail: svein.mathisen@bioinvent.com E-mail: cristina.glad@bioinvent.com Northbank Communications Katja Stout/Christelle Kerouedan Phone: +44 (0)20 7886 8150 Legal disclaimer This press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual out-come may deviate significantly from the scenarios described in this press release. Notes to editors: BioInvent International AB, which is listed on the O list of the Stockholm Stock Exchange (SAX:BINV), develops therapeutic antibodies against diseases where there is a significant unmet medical need. Antibodies are a strongly growing segment of the pharmaceutical market. BioInvent focuses on discovery and development of therapeutic antibodies, and documents their effect in pre-clinical and early clinical trials. Clinical development, marketing and distribution are conducted in cooperation with established pharmaceutical companies. Today BioInvent conducts innovative drug projects involving conditions such as HIV infection, thrombosis, cancer, atherosclerosis and diseases of the joints. These projects are based on a competitive technology platform that covers the entire chain from the n-CoDeRÒ antibody library for fast and efficient selection of human antibodies, to production in a facility fully approved for manufacturing biological drugs. The scope and strength of this platform is also utilised by partners in the development of new drugs. These partners include ALK-Abelló, Antisoma, Celltech, GlaxoSmithKline, Igeneon, ImmunoGen, OrbusNeich, Syngenta and XOMA. The Company, which currently has 92 employees, is located at Ideon in Lund. BioInvent International AB (publ) Co. reg. No. 556537-7263, Address: Sölvegatan 41 Mailing address: 223 70 LUND Tel: +46 (0)46 286 85 50
|
|
|
